---
layout: default
title: Sonidegib
parent: 僅模型預測 (L5)
nav_order: 404
evidence_level: L5
indication_count: 10
---

# Sonidegib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the drug-repurposing report template supplied in the system prompt to generate this report from the Evidence Pack. Note: I'm flagging one internal inconsistency in the pack rather than silently picking a side — see the caveat under "Quick Overview."

---

# Sonidegib: From Basal Cell Carcinoma to Medulloblastoma with Extensive Nodularity

## One-Sentence Summary

Sonidegib is a Smoothened (SMO) antagonist referenced in this evidence pack in the context of basal cell carcinoma (BCC) treatment (its structured "original indication" field is itself a data gap). The TxGNN model predicts a **99.90%** score for **medulloblastoma with extensive nodularity**, a Hedgehog-pathway-driven pediatric brain tumour subtype — but this evidence pack contains **zero registered clinical trials and zero indexed publications** for that specific drug–disease pair.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in structured drug record (data gap); referenced only indirectly as basal cell carcinoma (BCC) within the repurposing rationale text |
| Predicted New Indication | Medulloblastoma with extensive nodularity |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 (see caveat below) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

**Caveat on Evidence Level / Decision:** the pack's internal scoring field labels this candidate `L2` / `S2` / "Proceed with Guardrails," but its own `evidence.clinical_trials` and `evidence.literature` arrays for this indication are empty, and the rationale text explicitly states the count fields are 0. Applying the evidence-level rule literally (based on actual trial/literature counts, not the internal label) gives **L5 — model prediction only, no actual studies**. Combined with a **Blocking**-severity data gap (missing TFDA/SmPC label data, meaning safety pre-assessment cannot even begin), this report recommends **Hold** rather than the pack's internal "Proceed with Guardrails."

## Why is This Prediction Reasonable?

Sonidegib is a Smoothened (SMO) antagonist that selectively inhibits the Hedgehog signalling pathway. This mechanism-of-action detail comes from the repurposing rationale field, since the drug's own `original_moa` field is a data gap.

SHH-activated medulloblastoma — including the "extensive nodularity" subtype — is a pediatric brain tumour known to be driven by aberrant activation of the Hedgehog pathway. Mechanistically, this is one of the most direct links in the entire candidate list: SMO inhibition should, in principle, act on the same driver pathway underlying this tumour subtype, in the same way it does in Hedgehog-pathway-driven BCC.

For context, the pack also lists four other predicted indications (xeroderma pigmentosum, annular epidermolytic ichthyosis, epidermolysis bullosa simplex with mottled pigmentation, trichothiodystrophy photosensitive) at similarly high TxGNN scores. The pack's own rationale flags these as likely artefacts of knowledge-graph clustering around "rare photosensitive/genetic skin disease" — none has a plausible Hedgehog-pathway mechanism, and all are marked `Hold`. This makes medulloblastoma the only mechanistically credible candidate among the ten entries, even though it currently lacks any supporting trial or literature record in this pack.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Denmark Market Information

Sonidegib holds **no marketing authorisation in Denmark** (0 licenses on file; market status: not marketed). No national (Lægemiddelstyrelsen) or centralised (EMA) authorisation records are present in this evidence pack.

## Cytotoxicity

Sonidegib is an antineoplastic agent (Hedgehog-pathway inhibitor used in oncology), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (SMO/Hedgehog-pathway inhibitor) — not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Emetogenicity Classification | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Monitoring Items | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Handling Protection | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No key warnings, contraindications, or drug–drug interaction data are available in this evidence pack — the DDI query returned no results, and the TFDA/SmPC label data item is flagged as a **Blocking** data gap (`DG001`), meaning a Stage-1 safety pre-assessment cannot currently be performed.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- A Blocking-severity data gap (missing TFDA/SmPC label data) prevents any Stage-1 safety pre-assessment, regardless of the strength of the mechanistic rationale.
- Despite a mechanistically credible link (SMO inhibition → SHH-driven medulloblastoma), this evidence pack contains zero clinical trials and zero publications for this specific drug–disease pair — actual evidence level is L5, not the pack's internal L2 label.
- Sonidegib has no marketing authorisation in Denmark, so there is no existing regulatory or supply pathway to build on.

**To proceed, the following is needed:**
- TFDA/SmPC label data (warnings, contraindications) to close the Blocking data gap
- Confirmed original indication and MOA data for the drug record (currently both data gaps)
- A targeted literature/trial search specifically for sonidegib in SHH-activated medulloblastoma (e.g., pediatric brain tumour consortium studies), since none surfaced in the automated queries logged here
- Assessment of route/dosage-form compatibility for the pediatric population typically affected by this tumour subtype (currently marked "pending" with no data)
- Full DDI profile (current query returned no results)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

